10월 2026
scholar.google.com.pr
글로벌 순위
- -
국가 순위
- -
카테고리 순위
- -
Similarweb 추정 데이터를 표시합니다.
GA4를 연결하여 사이트의 지표를 공개적으로 검증하세요
성과를 반영하세요
Google Analytics를 연결하여 웹사이트의 트래픽 및 참여 지표를 확인하세요
이탈률
75.55%
방문당 페이지 수
1.89
평균 방문 시간
00:00:36
- 회사
- - -
- 업종
- - -
scholar.google.com.pr 상위 10개 경쟁사
10월 2026 기준 scholar.google.com.pr와 유사한 상위 10개 사이트는 키워드 트래픽, 오디언스 타기팅, 시장 중복도를 기준으로 scholar.google.com.pr와의 유사도에 따라 순위가 매겨집니다
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
이탈률
31.28%
방문당 페이지 수
6.01
평균 방문 시간
00:07:55
Explore options for your family: the YouTube Kids app or a parent supervised account for older kids & teens on YouTube, all with built-in protections.
이탈률
23.61%
방문당 페이지 수
11.07
평균 방문 시간
00:18:45
유사도 점수
86%academia.edu is a place to share and follow research.
이탈률
61.51%
방문당 페이지 수
2.35
평균 방문 시간
00:01:41
유사도 점수
80%Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
이탈률
46.91%
방문당 페이지 수
3.59
평균 방문 시간
00:03:06
We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying individual urgency to acquire resources. Treatments varied in the urgency process (frequent moderate versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Benchmarked against random allocation, karma achieves an (almost) Pareto improvement, despite subjects deviating from the theoretically optimal Nash bidding policy: maximum improvement is attained by subjects deviating by up to one karma bid unit on average, and positive improvement with deviations of up to 3-4 units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding being (weakly) favorable. They offer behaviorally robust lower bounds for karma's expected performance in human populations and guide its future implementation.
- 회사
- - -
- 업종
- - -
이탈률
39.23%
방문당 페이지 수
3.17
평균 방문 시간
00:04:08
유사도 점수
73%indexingmethod_automated - Search Results - PubMed
- 회사
- - -
- 업종
- - -
글로벌 순위
- -
국가 순위
- -
카테고리 순위
- -
이탈률
- -
방문당 페이지 수
- -
평균 방문 시간
- -
the world’s largest collection of open access research papers
- 회사
- - -
- 업종
- - -
이탈률
26.98%
방문당 페이지 수
5.13
평균 방문 시간
00:04:27
유사도 점수
65%Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- 회사
- - -
- 업종
- - -
이탈률
24.78%
방문당 페이지 수
3.71
평균 방문 시간
00:01:07
Learn more about our institutional models for librarians and the benefits for researchers.
이탈률
61.54%
방문당 페이지 수
1.75
평균 방문 시간
00:01:42
유사도 점수
61%DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
- 회사
- - -
- 업종
- - -
이탈률
19.35%
방문당 페이지 수
4.43
평균 방문 시간
00:01:51
유사도 점수
59%10월 2026 기준 scholar.google.com.pr의 상위 5개 경쟁사는 sciencedirect.com, youtube.com, academia.edu, researchgate.net 등입니다.
Similarweb의 월간 방문 데이터에 따르면, 10월 2026 기준 scholar.google.com.pr의 주요 경쟁사는 sciencedirect.com입니다. scholar.google.com.pr와 두 번째로 유사한 사이트는 youtube.com이며, 상위 3위를 차지하는 사이트는 academia.edu입니다.
researchgate.net는 scholar.google.com.pr와 네 번째로 유사한 웹사이트이며, 10월 2026 기준 arxiv.org가 5위입니다.
상위 10개 목록의 나머지 5개 경쟁사는 pubmed.ncbi.nlm.nih.gov, core.ac.uk, scienceopen.com, plos.org, doaj.org입니다.